Q1 25 EPS
$0.75
BEAT +11.52%
Est. $0.67
Q1 25 Revenue
$4.66B
BEAT +1.98%
Est. $4.57B
vs S&P Since Q1 25
-78.7%
TRAILING MARKET
BSX -44.1% vs S&P +34.6%
Market Reaction
Did BSX Beat Earnings? Q1 2025 Results
Boston Scientific kicked off 2025 with a standout first quarter, posting adjusted EPS of $0.75 against a consensus estimate of $0.67, a beat of 11.52%, while revenue of $4.66 billion topped the $4.57 billion estimate by 1.98% and grew 20.9% year over… Read more Boston Scientific kicked off 2025 with a standout first quarter, posting adjusted EPS of $0.75 against a consensus estimate of $0.67, a beat of 11.52%, while revenue of $4.66 billion topped the $4.57 billion estimate by 1.98% and grew 20.9% year over year, exceeding the company's own guided range of 17–19%. The primary engine behind the quarter was an explosive performance in the Cardiovascular segment, which surged 26.2% on a reported basis, led by Cardiology growing nearly 30% as the FARAPULSE pulsed field ablation platform continued to gain traction, including positive 12-month clinical data from the ADVANTAGE AF trial supporting the system's safety and efficacy in persistent atrial fibrillation. Management raised its full-year reported sales growth guidance to 15–17%, even as it absorbed an anticipated $200 million tariff headwind, projecting adjusted EPS of $2.87 to $2.94 for the year; second-quarter adjusted EPS guidance of $0.71 to $0.73 suggests continued momentum heading into the summer.
Key Takeaways
- • Cardiovascular segment organic growth of 25.6%, led by Cardiology at 31.2% organic growth
- • U.S. market growth of 31.1% driven by strong adoption of cardiac and interventional technologies
- • Strong product portfolio execution across all business units
- • Meaningful innovation and clinical science driving category leadership
BSX YoY Financials
Q1 2025 vs Q1 2024, source: SEC Filings
BSX Revenue by Segment
With YoY comparisons, source: SEC Filings
BSX Revenue by Geography
With YoY comparisons, source: SEC Filings
“We delivered an exceptional quarter to start the year, reflecting the effectiveness of our highly engaged global team and the strength of our product portfolio.”
— Mike Mahoney, Q1 2025 Earnings Press Release
BSX Earnings Trends
BSX vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
BSX EPS Trend
Earnings per share: estimate vs actual
BSX Revenue Trend
Quarterly revenue: estimate vs actual
BSX Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 | — | $0.80 | — | $5.20B | +0.60% |
| Q4 25 BEAT FY | $0.78 | $0.80 | +2.56% | $5.29B | +0.04% |
| FY Full Year | $3.04 | $3.06 | +0.80% | $20.07B | +0.01% |
| Q3 25 BEAT | $0.71 | $0.75 | +5.09% | $5.07B | +1.83% |
| Q2 25 BEAT | $0.73 | $0.75 | +3.42% | $5.06B | +3.39% |
| Q1 25 BEAT | $0.67 | $0.75 | +11.52% | $4.66B | +1.98% |